SCHEMBL4091345

SCHEMBL4091345

Fc1ccc(-c2nc(N3CCOCC3)c3ccccc3n2)c(F)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 6/20 0.66
CYP3A4 P08684 6/20 0.66
MAPK1 P28482 5/20 0.66
USP2 O75604 4/20 0.66
CLK4 Q9HAZ1 4/20 0.66
CYP2D6 P10635 3/20 0.66
ALDH1A1 P00352 7/20 0.63
TSHR P16473 5/20 0.63
ALOX15 P16050 3/20 0.63
CYP2C19 P33261 2/20 0.63
CYP2C9 P11712 1/20 0.63
CASP7 P55210 1/20 0.63
HIF1A Q16665 1/20 0.62
METAP1 P53582 1/20 0.60
LMNA P02545 3/20 0.58
HTT P42858 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.56
TDP1 Q9NUW8 1/20 0.56
KDM4E B2RXH2 4/20 0.56
HPGD P15428 3/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4090989 0.90 HIF1A (0.76) CYP1A2CYP3A4MAPK1USP2CLK4
SCHEMBL4085263 0.89 HIF1A (0.79) CYP1A2CYP3A4MAPK1USP2ALDH1A1
SCHEMBL4089129 0.88 HIF1A (0.76) CYP1A2CYP3A4MAPK1USP2CLK4
SCHEMBL4090769 0.86 CYP3A4 (0.67) CYP1A2CYP3A4MAPK1USP2CLK4
SCHEMBL1084484 0.86 CYP1A2 (0.60) CYP1A2CYP3A4MAPK1USP2CLK4
SCHEMBL5804844 0.86 CYP1A2 (0.63) CYP1A2CYP3A4CLK4CYP2D6ALDH1A1
SCHEMBL1083986 0.86 CYP1A2 (0.60) CYP1A2CYP3A4MAPK1USP2CLK4
SCHEMBL5788913 0.86 CYP1A2 (0.63) CYP1A2CYP3A4CLK4CYP2D6ALDH1A1
SCHEMBL13342122 0.83 HTT (0.74) CYP1A2CYP3A4MAPK1USP2CLK4
SCHEMBL4089767 0.81 GBA1 (0.60) CYP1A2CYP3A4MAPK1USP2CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE CNR2, CNR1, GPR18 CYP1A2 2477/4885CYP3A4 2113/4885MAPK1 2435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.